<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05115500</url>
  </required_header>
  <id_info>
    <org_study_id>JD-LK-2021-121-01</org_study_id>
    <nct_id>NCT05115500</nct_id>
  </id_info>
  <brief_title>ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)</brief_title>
  <official_title>Antibody-Drug Conjugate Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment Advanced Refractory Solid Tumors With HER-2 Positive(PRaG3.0)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm, Phase II investigator-initiated trial of antibody-drug&#xD;
      conjugate combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF&#xD;
      and IL-2 for treatment of advanced refractory solid tumors with HER-2 positive&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate （ORR）</measure>
    <time_frame>24 months</time_frame>
    <description>Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>PFS was defined as the time from the first administration of study treatment to the first occurrence of disease progression as determined by investigator using RECIST v1.1 or death from any cause, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>24 months</time_frame>
    <description>DCR was defined as the percentage of participants with a complete response (CR), partial response (PR), or stable disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>OS was defined as the time from the first administration of study treatment to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>24 months</time_frame>
    <description>rate of adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Carcinoma</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2</intervention_name>
    <description>RC48-ADC combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2</description>
    <arm_group_label>ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18 years and above;&#xD;
&#xD;
          2. Diagnosed with histologically or cytologically-confirmed, HER2-positive(IHC 1+, 2+ or&#xD;
             3+), standard treatment is ineffective (disease progresses after treatment) or locally&#xD;
             advanced or metastatic malignant solid tumor patients who cannot tolerate standard&#xD;
             therapy, cannot receive or do not have standard therapy;&#xD;
&#xD;
          3. ECOG(Eastern Cooperative Oncology Group) performance is 0-3;&#xD;
&#xD;
          4. Life expectancy greater than 3 months;&#xD;
&#xD;
          5. T lymphocyte absolute value ≥0.5 upper limit of normal (ULN), absolute neutrophil&#xD;
             count(ANC)≥1.0 x 10(9)/L；serum aspartate transaminase (AST) and serum alanine&#xD;
             transaminase (ALT) ≤3.0*ULN, or AST and ALT≤5*ULN with hepatic metastasis; Total serum&#xD;
             creatinine ≤1.5*ULN；&#xD;
&#xD;
          6. Signed informed consent form；&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current pregnancy or lactation；&#xD;
&#xD;
          2. History of other malignant tumors within 5 years prior to dose administration, expect&#xD;
             for：malignancies that can be cured after treatment (including but not limited to&#xD;
             adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell&#xD;
             skin cancer);&#xD;
&#xD;
          3. Uncontrolled epilepsy, central nervous system diseases or mental illness;&#xD;
&#xD;
          4. Currently active clinically significant cardiovascular disease such as uncontrolled&#xD;
             arrhythmia, congestive heart failure, or greater than or equal to Class 2 congestive&#xD;
             heart failure as defined by the New York Heart Association Functional Classification,&#xD;
             or history of myocardial infarction unstable angina, or acute coronary syndrome within&#xD;
             6 months prior to enrollment in the study;&#xD;
&#xD;
          5. Received allogeneic hematopoietic stem cell transplantation or solid organ&#xD;
             transplantation;&#xD;
&#xD;
          6. Other serious, uncontrolled concomitant diseases that may affect protocol compliance&#xD;
             or interpretation of outcomes, including active opportunistic infections or advanced&#xD;
             (severe) infections, uncontrolled diabetes;&#xD;
&#xD;
          7. Allergic to any of the ingredients used in the study;&#xD;
&#xD;
          8. A history of immunodeficiency, including HIV positive or other acquired or congenital&#xD;
             immunodeficiency disease, or a history of organ transplantation, or other&#xD;
             immune-related disease requiring long-term oral hormone therapy;&#xD;
&#xD;
          9. Acute and chronic tuberculosis infection;&#xD;
&#xD;
         10. Other disorders with clinical significance according to the researcher's judgment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Liyuan Zhang, doctor</last_name>
    <phone>0512-67784829</phone>
    <email>zhangliyuan126@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Bethune Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xin Jiang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Changzhou</name>
      <address>
        <city>Changzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wendong Gu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lili Yu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangyin Peoples Hospital</name>
      <address>
        <city>Jiangyin</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jian Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shangdong University</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Bingxu Tan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Dali Han</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Kunshan</name>
      <address>
        <city>Kunshan</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Minbin Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Li Yin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital of Chinese Medicine</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Dahai Yu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuandong Cao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jing Yan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Nantong University</name>
      <address>
        <city>Nantong</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiancheng Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qiao Qiao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Liyuan zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suzhou Municipal Hospital</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jundong Zhou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>songbing Qin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weihai Municipal Hospital</name>
      <address>
        <city>Weihai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Fujun Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangnan University</name>
      <address>
        <city>Wuxi</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ke Gu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianshe Wang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 4, 2021</study_first_submitted>
  <study_first_submitted_qc>November 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

